← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #1787 OF 1,916 MOST-CITED

Maintenance - concurrence

FDA cited this observation 5 times across 5 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics5
BY FISCAL YEAR
FY20251
FY20231
FY20211
FY20191
FY20181

How FDA worded it — real examples

Records are not made concurrently with the performance of each step in the manufacture of products.

Loyola Univ Medical Center · Maywood, Illinois · Biologics · 2024-12-05

Records are not made concurrently with the performance of each step in the of products.

The Abraham J. And Phyllis Katz Cord Blood · Warrensville Heights, Ohio · Biologics · 2023-09-15

Records are not made concurrently with the performance of each step in the distribution of products.

U.S. Dept. of Veterans Affairs, Northport VA Medical Center · Northport, New York · Biologics · 2021-05-18

Records are not made concurrently with the performance of each step in the manufacture of products.

HRF, Inc · Raleigh, North Carolina · Biologics · 2019-03-20

Records are not made concurrently with the performance of each step in the distribution of products.

Nassau Health Care Corporation d/b/a/ NuHealth · East Meadow, New York · Biologics · 2018-02-22

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →